Atherosclerosis III: Management
Pharmacovigilance
Cross-reactivity
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Oct 15, 2025

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
1Department of Neurology, Mayo Clinic, Rochester, MN.
No abstract available in PubMed .
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016